Diagnosing CKD Earlier & More Precisely to Expand Treatable Populations, Improve Trial Recruitment & Prevent Progression

• Identifying why CKD remains underdiagnosed despite relevant information already existing in patient records
• Driving differential diagnosis beyond broad CKD labels to uncover IgAN, FSGS, Alport and other underlying causes
• Connecting earlier diagnosis with appropriate therapy, clinical trial access and improved long-term outcomes

Speakers: